Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer

Background Several studies have examined the clinical significance of metabolic response in primary tumours by [18F]fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) in patients with oesophageal cancer who undergo neoadjuvant therapy. The relevance of the metabolic response in lymph node...

Full description

Saved in:
Bibliographic Details
Published in:British journal of surgery 2013-10, Vol.100 (11), p.1490-1497
Main Authors: Miyata, H., Yamasaki, M., Takahashi, T., Murakami, K., Kurokawa, Y., Nakajima, K., Takiguchi, S., Mori, M., Doki, Y.
Format: Article
Language:English
Subjects:
Carcinoma, Squamous Cell - diagnostic imaging
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - surgery
Disease-Free Survival
Esophageal Neoplasms - diagnostic imaging
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - surgery
Female
Fluorodeoxyglucose F18
Humans
Lymph Nodes - diagnostic imaging
Lymphatic Metastasis
Male
Middle Aged
Multimodal Imaging - methods
Multimodal Imaging - mortality
Neoadjuvant Therapy
Radionuclide Imaging
Radiopharmaceuticals
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Several studies have examined the clinical significance of metabolic response in primary tumours by [18F]fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) in patients with oesophageal cancer who undergo neoadjuvant therapy. The relevance of the metabolic response in lymph nodes is unclear. Methods Consecutive patients with oesophageal cancer who underwent neoadjuvant chemotherapy followed by surgery were studied. 18F‐FDG‐PET was performed before and 2–3 weeks after completion of neoadjuvant chemotherapy, assessing FDG uptake in primary tumours and lymph nodes considered to be metastatic. Results Before therapy, 156 (73·9 per cent) of 211 patients had PET‐positive nodes, of whom 89 (57.1 per cent) had no evidence of metabolic activity in these lymph nodes following chemotherapy. There was a significant relationship between post‐treatment lymph node status assessed by FDG‐PET and numbers of pathologically confirmed metastatic lymph nodes. Patients with post‐treatment PET‐positive nodes had shorter survival than those without (5‐year survival rate 25 versus 62·6 per cent; P 
ISSN:0007-1323
1365-2168
DOI:10.1002/bjs.9253